Literature DB >> 27855321

Plasmacytoid dendritic cells in autoimmunity.

Santosh K Panda1, Roland Kolbeck1, Miguel A Sanjuan2.   

Abstract

Plasmacytoid dendritic cells (pDC) is a unique cell population that produces large amounts of type I interferon upon recognition of nucleic acids placing them at the crossroad of both innate and adaptive immunity. Their ability to produce interferon makes them central to anti-viral responses. They are also responsive to circulating autoantibodies bound to nuclear antigens and in that scenario the release of interferons initiate self-directed immune responses. There are now a growing number of autoimmune disorders where unabated activation of pDC is suspected to be pathogenic. Here, we discuss the different mechanisms responsible for breaking tolerance to self-nucleic acids by pDC, including the novel role of IgE autoantibodies in systemic lupus erythematosus. We also summarized the recent progress on therapies undergoing clinical testing that target either pDC or type I interferons.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27855321     DOI: 10.1016/j.coi.2016.10.006

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  19 in total

1.  Exposure to Environmental Toxins and Autoimmune Conditions.

Authors:  Datis Kharrazian
Journal:  Integr Med (Encinitas)       Date:  2021-04

Review 2.  Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus.

Authors:  Nasim Bolouri; Maryam Akhtari; Elham Farhadi; Reza Mansouri; Seyedeh Tahereh Faezi; Ahmadreza Jamshidi; Mahdi Mahmoudi
Journal:  Inflamm Res       Date:  2022-03-17       Impact factor: 4.575

3.  Plasmacytoid dendritic cells promote the pathogenesis of Sjögren's syndrome.

Authors:  Jing Zhou; Xiaofeng Zhang; Qing Yu
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-11-12       Impact factor: 5.187

4.  Aim2 Couples With Ube2i for Sumoylation-Mediated Repression of Interferon Signatures in Systemic Lupus Erythematosus.

Authors:  Ailing Lu; Shuxian Wu; Junling Niu; Mengmeng Cui; Mengdan Chen; William L Clapp; Betsy J Barnes; Guangxun Meng
Journal:  Arthritis Rheumatol       Date:  2021-07-07       Impact factor: 15.483

Review 5.  Pathogenesis and Therapeutic Mechanisms in  Immune Thrombocytopenia (ITP).

Authors:  Anne Zufferey; Rick Kapur; John W Semple
Journal:  J Clin Med       Date:  2017-02-09       Impact factor: 4.241

Review 6.  Hedgehog Signaling Links Chronic Inflammation to Gastric Cancer Precursor Lesions.

Authors:  Juanita L Merchant; Lin Ding
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-01-16

Review 7.  Plasmacytoid Dendritic Cells: Development, Regulation, and Function.

Authors:  Boris Reizis
Journal:  Immunity       Date:  2019-01-15       Impact factor: 31.745

Review 8.  Regulation of iNOS on Immune Cells and Its Role in Diseases.

Authors:  Qingjie Xue; Yingchun Yan; Ruihua Zhang; Huabao Xiong
Journal:  Int J Mol Sci       Date:  2018-11-29       Impact factor: 5.923

9.  Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.

Authors:  Jeffrey M Riggs; Richard N Hanna; Bhargavi Rajan; Kamelia Zerrouki; Jodi L Karnell; Divya Sagar; Inna Vainshtein; Erika Farmer; Kimberly Rosenthal; Chris Morehouse; Melissa de Los Reyes; Kevin Schifferli; Meina Liang; Miguel A Sanjuan; Gary P Sims; Roland Kolbeck
Journal:  Lupus Sci Med       Date:  2018-04-05

10.  Phenotypic Analysis of Human Lymph Nodes in Subjects With New-Onset Type 1 Diabetes and Healthy Individuals by Flow Cytometry.

Authors:  Jennie H M Yang; Leena Khatri; Marius Mickunas; Evangelia Williams; Danijela Tatovic; Mohammad Alhadj Ali; Philippa Young; Penelope Moyle; Vishal Sahni; Ryan Wang; Rejbinder Kaur; Gillian M Tannahill; Andrew R Beaton; Danielle M Gerlag; Caroline O S Savage; Antonella Napolitano Rosen; Frank Waldron-Lynch; Colin M Dayan; Timothy I M Tree
Journal:  Front Immunol       Date:  2019-10-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.